申请人:Pfizer Inc.
公开号:US07321040B2
公开(公告)日:2008-01-22
The present invention relates to novel triazolo-pyridines of the formula
wherein X is >CH2, >NH, sulfur, >S═O, >SO2 or oxygen; wherein said >CH2 and >NH may optionally be substituted with a suitable substituent;
R1 is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents;
R2 is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents;
s is an integer from 0-4;
R3 is R4, R5—(NR6)—, R5—S—, R5—(S═O)—, R5—(SO2)—, R5—SO2—NR6—, R5—(NR6)—SO2—, R5—O—, R5—(C═O)—, R5—(NR6)—(C═O)—, R5—(C═O)—NR6—, R5—O—(C═O)—, R5—(C═O)—O—, R5—CR7═CR8— or R5—C≡C—; such that the molecular weight of R3 is less than 500 AMU, preferably less than 250 AMU;
R4, R5 and R6 are each selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents;
or a pharmaceutically acceptable salt thereof;
to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
本发明涉及新型三唑并
吡啶的公式,其中X为>
CH2、>NH、
硫、>S═O、>SO2或氧;其中所述的> 和>NH可以选择性地用适当的取代基取代;R1选自氢、(C1-C6)烷基和其他适当的取代基组成的群;R2选自氢、(C1-C6)烷基和其他适当的取代基组成的群;s为0-4的整数;R3为R4、R5—(NR6)—、R5—S—、R5—(S═O)—、R5—(SO2)—、R5—SO2—NR6—、R5—(NR6)—SO2—、R5—O—、R5—(C═O)—、R5—(NR6)—(C═O)—、R5—(C═O)—NR6—、R5—O—(C═O)—、R5—(C═O)—O—、R5—CR7═CR8—或R5—C≡C—;其中R3的分子量小于500
AMU,优选小于250
AMU;R4、R5和R6各自选自氢、(C1-C6)烷基和其他适当的取代基;或其药学上可接受的盐;以及制备它们的中间体、含有它们的制药组合物和它们的药用用途。本发明的化合物是
MAP激酶的强力
抑制剂。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病中有用。